2019
Regulated necrosis and failed repair in cisplatin-induced chronic kidney disease
Landau SI, Guo X, Velazquez H, Torres R, Olson E, Garcia-Milian R, Moeckel GW, Desir GV, Safirstein R. Regulated necrosis and failed repair in cisplatin-induced chronic kidney disease. Kidney International 2019, 95: 797-814. PMID: 30904067, PMCID: PMC6543531, DOI: 10.1016/j.kint.2018.11.042.Peer-Reviewed Original ResearchConceptsChronic kidney diseaseKidney diseaseKidney injuryCisplatin-induced chronic kidney diseaseCisplatin-induced acute kidney injuryToll-like receptor 2Regulated necrosis pathwaysReversible kidney injuryAcute kidney injuryChronic kidney injuryProximal tubular damageKidney injury markersDoses of cisplatinEvidence of fibrosisMechanisms of progressionEffective chemotherapeutic agentWestern blot analysisFirst doseInjury markersIntraperitoneal cisplatinSignificant nephrotoxicityTubular damageKidney functionSecond doseCisplatin administration
2013
Renalase protects against cisplatin acute kidney injury in mice
Desir G, Wang L, Velazquez H, Moeckel G, Safirstein R. Renalase protects against cisplatin acute kidney injury in mice. The FASEB Journal 2013, 27: 910.7-910.7. DOI: 10.1096/fasebj.27.1_supplement.910.7.Peer-Reviewed Original ResearchCisplatin acute kidney injuryAcute kidney injuryRenalase expressionKidney injuryCisplatin-induced acute kidney injuryIschemic acute kidney injuryRenal injury scoreUseful therapeutic optionHK-2 cellsImportant clinical syndromeRenalase deficiencyTubular necrosisPro-survival signalsTherapeutic optionsClinical syndromeInjury scorePlasma creatinineKO miceEffective therapyRenalaseBCL2 expressionMarked reductionProtective actionCaspase-3Injury